Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials

@article{Kramer2011EfficacyAS,
  title={Efficacy and safety of topiramate on weight loss: a meta‐analysis of randomized controlled trials},
  author={Caroline K Kramer and Cristiane Bauermann Leitao and Lana C Pinto and Lu{\'i}s Henrique Canani and Mirela Jobim de Azevedo and Jorge Luiz Gross},
  journal={Obesity Reviews},
  year={2011},
  volume={12}
}
Topiramate was associated with weight loss in clinical trials. We summarize the evidence on the efficacy and safety of topiramate in the treatment of overweight/obesity. The databases Medline, Embase, and Cochrane were searched. Randomized controlled studies with at least 16 weeks of duration that report the effect of topiramate on weight loss and adverse events were eligible for inclusion. Ten studies were included (3320 individuals). Patients treated with topiramate lost an average of 5.34 kg… Expand
Topiramate monotherapy for weight reduction in patients with type 2 diabetes mellitus: A systematic review and meta-analysis.
TLDR
Topiramate monotherapy reduced weight in obese type 2 diabetes patients, but increased adverse events including serious adverse events, so clinicians should generally avoid use of topiramate alone for this indication. Expand
Clinical inquiries: is immediate-release topiramate an effective treatment for adult obesity?
TLDR
Topiramate increases the chances of losing 5% or more of baseline body weight (BBW) with a number needed to treat (NNT) of 3 (95% CI, 2-3) and 10% ormore of BBW with an NNT of 4 (95%) however, approximately 17% of patients discontinue the drug because of adverse effects. Expand
Efficacy and safety of topiramate in binge eating disorder: a systematic review and meta-analysis.
TLDR
Preliminary findings support a possible efficacy of topiramate for the treatment of BED, even if safety concerns could limit the practical use of this treatment in BED subjects. Expand
Effect of Topiramate on Weight Gain in Patients Receiving Atypical Antipsychotic Agents
TLDR
It is found that patients receiving topiramate lost weight or had attenuated weight gain compared to control patients, and a meta-analysis shows that usingTopiramate can prevent or reduce weight gain associated with AAPs. Expand
[Effect of Topiramate on Drug Associated Weight Gain of Patients with Schizophrenia and Bipolar I Disorders: A Dose Ranging Randomized Trial].
TLDR
All doses of 50, 100, and 200mg were shown effective in preventing olanzapine-related obesity in schizophrenic and/or bipolar patients. Expand
Pharmacotherapy of Obesity: Clinical Trials to Clinical Practice
Purpose of ReviewThis review provides an overview of the current state of drug therapy for obesity, with a focus on four new drug therapies—lorcaserin, phentermine/topiramate, naltrexone/bupropion,Expand
A Review of the Combination of Phentermine and Topiramate Extended-Release for Weight Loss
The Food and Drug Administration recently approved the combination of phentermine and extended-release topiramate (PHN/TPM) for weight loss. This is one of only two weight-loss agents to arrive onExpand
A review of topiramate and phentermine: a combined therapeutic approach for obesity
TLDR
The investigational combination of phentermine and topiramate, an antiepileptic drug with known weight-loss effects, as a proposed anti-obesity intervention achieves weight loss of a magnitude that meets the expectations of the US FDA along with improvement of some obesity-related risks. Expand
Pharmacotherapy for Patients with Obesity.
TLDR
With the availability of 4 new drugs since 2012, clinicians in the US now have more tools for long-term weight management, but the quality of pharmacotherapy clinical investigations needs considerable improvement. Expand
Topiramate
Introduction Obesity is associated with significant morbidity and mortality and its incidence has increased by 26% since 2016, with approximately 20% of adults in the UK classified as obese (bodyExpand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 47 REFERENCES
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
TLDR
The findings suggest that 20 mg per day rimonabant increases the risk of psychiatric adverse events--ie, depressed mood disorders and anxiety-despite depressed mood being an exclusion criterion in these trials. Expand
Efficacy and safety of topiramate in the treatment of obese subjects with essential hypertension.
TLDR
In conclusion, topiramate produced clinically relevant effects in reducing body weight and BP, with generally mild to moderate adverse effects. Expand
Topiramate: long-term maintenance of weight loss induced by a low-calorie diet in obese subjects.
TLDR
During a treatment period of 44 weeks, TPM was generally well tolerated, and subjects maintained weight loss initially achieved by a low-calorie diet-and produced additional clinically significant weight loss beyond that achieved byA low-Calorie diet. Expand
A 6-month randomized, placebo-controlled, dose-ranging trial of topiramate for weight loss in obesity.
TLDR
TPM produced significantly greater weight loss than placebo at all doses, with greater percentages of TPM-treated patients lost at least 5% or 10% of body weight compared with placebo. Expand
Long term pharmacotherapy for obesity and overweight: updated meta-analysis
TLDR
Orlistat, sibutramine, and rimonabant modestly reduce weight, have differing effects on cardiovascular risk profiles, and have specific adverse effects. Expand
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects
TLDR
Topiramate treatment of obese subjects over the course of 1 y resulted in clinically significant weight loss and improvements were also observed in blood pressure and glucose tolerance. Expand
A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects
TLDR
Topiramate treatment of obese subjects over the course of 1 y resulted in clinically significant weight loss and improvements were also observed in blood pressure and glucose tolerance. Expand
Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study
TLDR
Topiramate was effective for weight reduction and improvement in glycemic control in obese subjects with type 2 diabetes treated with metformin monotherapy and experienced statistically significant decreases in systolic blood pressure. Expand
Meta-Analysis: Pharmacologic Treatment of Obesity
TLDR
This review of 79 clinical trials involving diet plus the obesity drugs sibutramine, orlistat, fluoxetine, sertraline, bupropion, topiramate, or zonisamide shows that these medications can lead to modest weight reductions of approximately 5 kg or less at 1 year. Expand
Effect of sibutramine on weight maintenance after weight loss: a randomised trial
TLDR
Changes in concentrations of HDL cholesterol, VLDL cholesterol, and triglyceride, but not LDL cholesterol, exceed those expected either from weight loss alone or when induced by other selective therapies for low concentrations of LDL cholesterol relating to coronary heart disease. Expand
...
1
2
3
4
5
...